Malignant hyperthermia: Advances in clinical management and diagnosis

British Journal of Anaesthesia

Volumn 85, Issue 1, 2000, Pages 118-128

  Hopkins, P M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anaesthetics; Genetic factors; Hyperthermia; Malignant hyperthermia; Volatile

Indexed keywords

CHLOROCRESOL; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; LOCAL ANESTHETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; PHENOTHIAZINE; RYANODINE;

CLINICAL FEATURE; HEREDITY; HUMAN; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0034044116     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/85.1.118     Document Type: Article

References (129)

1. Adeokun AM, West SP, Ellis FR et al. The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. Am J Hum Genet 1997; 60: 833-41
2. Adnet PJ, Krivosic-Horber RM, Adamantidis MM et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 676-80
3. Adnet PJ, Reyford H, Krivosic-Horber RM. Neuroleptic malignant syndrome. In: Hopkins PM, Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press, 1996; 223-38
4. Adnet PJ, Reyford H, Tavernier BM et al. In vitro human masseter muscle hypersensitivity: a possible explanation for increase in masseter tone. J Appl Physiol 1996; 80: 1547-53
5. Adnet PJ Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85: 129-35.
6. Allen GC, Brubaker CL. Human malignant hyperthermia associated with desflurane anesthesia. Anesth Analg 1998; 86: 1328-31
7. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 88: 579-88
8. Bellamy MC, Hopkins PM, Halsall PJ, Ellis FR. Study into the incidence of methaemoglobinaemia after prilocaine 3:1 block. Anaesthesia 1992; 47: 1084-5
9. Bianchi CP, Bolton TC. Action of local anesthetics on coupling systems in muscle. J Pharmacol Exp Ther 1967; 157: 388-405
10. Britt BA. Preanesthetic diagnosis of malignant hyperthermia. Int Anesthesiol Clin 1979; 17: 63-96
11. Britt BA, Gordon RA. Three cases of malignant hyperthermia with special consideration of management. Can Anaesth Soc J 1969; 16: 99-105
12. Britt BA, Webb GE, LeDuc C. Malignant hyperthermia induced by curare. Can Anaesth Soc J 1974; 21: 371-5
13. Brownell AK. Malignant hyperthermia: relationship to other diseases. Br J Anaesth 1988; 60: 303-8
14. Burns AP, Hopkins PM, Hall G, Pusey CD. Rhabdomyolysis and acute renal failure in unsuspected malignant hyperpyrexia. Q J Med 1993; 86: 431-4
15. 2+ -permeable pore of the calcium release channel. J Biol Chem 1987; 262: 16636-43
16. Casson H, Downes H. Ryanodine toxicity as a model of malignant hyperthermia. In: Aldrete JA, Britt BA, eds. Malignant Hyperthermia. New York: Grune & Stratton, 1978; 3-10
17. Christian AS, Ellis FR, Halsall PJ. Is there a relationship between masseteric muscle spasm and malignant hyperpyrexia? Br J Anaesth 1989; 62: 540-4
18. Clarke IM, Ellis FR. An evaluation of procaine in the treatment of malignant hyperpyrexia. Br J Anaesth 1975; 47: 17-21
19. Cullen WG. Malignant hyperpyrexia during general anaesthesia; a report of two cases. Can Anaesth Soc J 1966; 13: 437-43
20. Curran JL, Hall WJ, Halsall PJ et al. Segregation of malignant hyperthermia, central core disease and chromosome 19 markers. Br J Anaesth 1999; 83: 217-22
21. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet 1960; ii: 45
22. Denborough MA, Foster JFA, Lovell RRH, Maplestone DA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962; 34: 395-6
23. Deufel T, Golla A, Iles D et al. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet 1992; 50: 1151-61
24. Deufel T, Sudbrak R, Feist Y et al. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHSI region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 1995; 56: 1334-42
25. Dickinson JG. Exertional heat stroke: predisposing factors, clinical features, treatment and prevention. In: Hopkins PM, Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press, 1996; 20-41
26. Dinsmore J, Hall GM. Porcine stress syndrome. In: Hopkins PM, Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press, 1996; 202-20
27. Ducart A, Adnet P, Renaud B, Riou B, Krivosic-Horber R. Malignant hyperthermia during sevoflurane administration. Anesth Analg 1995; 80: 609-11
28. Ellis FR, Harriman DG. A new screening test for susceptibility to malignant hyperpyrexia. Br J Anaesth 1973; 45: 638
29. Ellis FR, Smith G. Symposium on malignant hyperthermia. Br J Anaesth 1988; 60: 251-319
30. Ellis FR, Keaney NP, Harriman DG et al. Screening for malignant hyperpyrexia. BMJ 1972; iii: 559-61
31. Ellis FR, Halsall PJ, Christian AS. Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands. Anaesthesia 1990; 45: 838-41
32. Ellis FR, Halsall PJ, Hopkins PM. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia? BrJ Anaesth 1992; 69: 468-70
33. Ellis FR, Hopkins PM, Halsall PJ, Christian AS. Masseter muscle spasm and the diagnosis of malignant hyperthermia susceptibility. Anesth Analg 1992; 75: 143-6
34. Enright SM, Hopkins PM, Halsall PJ, Ellis FR. Can enoximone trigger malignant hyperthermia? Br J Anaesth 1997; 78: 460P
35. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia susceptibility. BrJ Anaesth 1984; 56: 1267-9
36. European Malignant Hyperpyrexia Group. Laboratory diagnosis of malignant hyperthermia susceptibility (MHS). Br J Anaesth 1985; 57: 1038
37. Fagerlund TH, Ording H, Bendixen D, Islander G, Ranklev Twetman E, Berg K. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation. Clin Genet 1997; 52: 416-21
38. Fairhurst AS, Hamamoto V, Macri J. Modification of ryanodine toxicity by dantrolene and halothane in a model of malignant hyperthermia. Anesthesiology 1980; 53: 199-204
39. Fletcher JE, Rosenberg H, Lizzo FH. Effects of droperidol, haloperidol and ketamine on halothane, succinylcholine and caffeine contractures: implications for malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 187-92
40. Fletcher JE, Rosenberg H, Aggarwal M. Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies. Anesthesiology 1999; 90: 654-61
41. Fu ES, Scharf JE, Mangar D, Miller WD. Malignant hyperthermia involving the administration of desflurane. Can J Anaesth 1996; 43: 687-90
42. Fujii J, Otsu K, Zorzato F et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-51
43. Gillard EF, Otsu K, Fujii J et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991; 11: 751-5
44. Gilly H, Musat I, Fricker R, Bittner RE, Steinbereithner K, Kress HG. Classification of malignant hyperthermia-equivocal patients by 4-chloro-m-cresol. Anesth Analg 1997; 85: 149-54
45. Gronert GA, Antognini JF. Clinical management of malignant hyperthermia. In: Hopkins PM, Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press, 1996; 119-31
46. Gronert GA, White DA. Failure of norepinephrine to initiate porcine malignant hyperthermia. Pflugers Arch 1988; 411: 226-8
47. Gronert GA, Milde JH, Theye RA. Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 1977; 47: 411-5
48. Haberman ML. Malignant hyperthermia. An allergic reaction to thioridazine therapy. Arch Int Med 1978; 138: 800-1
49. Hackl W, Mauritz W, Schemper M, Winkler M, Sporn P, Steinbereithner K. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs. Br J Anaesth 1990; 64: 425-9
50. Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesth 1991; 66: 138-40
51. Hall GM, Lister D. Procaine and malignant hyperthermia. Lancet 1974; i: 208
52. Halsall PJ. Clinical presentation of malignant hyperthermia. In: Hopkins PM, Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge Cambridge University Press, 1996; 107-18
53. Halsall PJ, Ellis FR. Does postoperative pyrexia indicate malignant hyperthermia susceptibility? Br J Anaesth 1992; 68: 209-10
54. Halsall PJ, Bridges LR, Ellis FR, Hopkins PM. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry 1996; 61: 119-21
55. Harrison GG, Isaacs H. Malignant hyperthermia. An historical vignette. Anaesthesia 1992; 47: 54-6
56. Hartung E, Koob M, Anetseder M et al. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine-and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol Scand 1996; 40: 437-44
57. Healy SJ, Heffron JJ, Lehane M, Bradley DG, Johnson K, McCarthy TV. Diagnosis of susceptibility to malignant hyperthermia with lanking DNA markers. BMJ 1991; 303: 1225-8
58. Heffron JJ, Mitchell G. Procaine for malignant hyperthermia. New Engl J Med 1975; 292: 266-7
59. Hopkins PM. The effect of suxamethonium on intracellular calcium ion concentration of isolated rat skeletal muscle. Br J Anaesth 1994; 73: 717P
60. Hopkins PM. Masseter muscle spasm. In: Goldstone JC, Pollard BJ, eds. Handbook of Clinical Anaesthesia. London: Churchill Livingstone, 1996; 646-7
61. Hopkins PM, Ellis FR. Inherited disease affecting anaesthesia. In: Healy TEJ, Cohen PJ, eds. A Practice of Anaesthesia, 6th edn. London: Edward Arnold, 1995; 938-52
62. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991; 338: 1491-2
63. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991; 66: 611-3
64. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders. Br J Anaesth 1993; 70: 397-401
65. Hopkins PM, Halsall PJ, Ellis FR. Diagnosing malignant hyperthermia susceptibility. Anaesthesia 1994; 49: 373-5
66. Hopkins PM, Ellis FR, Halsall PJ, Stewart AD. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Anesth Analg 1997; 84: 648-56
67. Hopkins PM, Hartung E, Wappler F, The European Malignant Hyperthermia Group. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 1998; 80: 389-94
68. Iles DE, Segers B, Sengers RC et al. Genetic mapping of the beta 1-and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum Mol Genet 1993; 2: 863-8
69. Iles DE, Lehmann-Horn F, Scherer SW et al. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994; 3: 969-75
70. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79: 5-9
71. Islander G, Henriksson KG, Ranklev-Twetman E. Malignant hyperthermia susceptibility without central core disease (CCD) in a family where CCD is diagnosed. Neuromusc Disord 1995; 5: 125-7
72. Johnson K. Malignant hyperthermia hots up. Hum Mol Genet 1993; 2: 849
73. Kawana Y, Iino M, Horiuti K et al. Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed Res 1992; 13: 287-97
74. Keating KE, Giblin L, Lynch PJ et al. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. J Med Genet 1997; 34: 291-6
75. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-5
76. Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 1987; 66: 547-50
77. Larach MG, Landis JR, Bunn JS, Diaz M. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry. Anesthesiology 1992; 76: 16-27
78. Larach MG, Localio AR, Allen GC et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9
79. Laurence AS. Serum myoglobin and creatine kinase following surgery. Br J Anaesth 2000; 85: 763-6.
80. Laurence AS, Vanner GK, Collins W, Hopkins PM. Serum and urinary myoglobin following an aborted malignant hyperthermia reaction. Anaesthesia 1996; 51: 958-61
81. Leary NP, Ellis FR. Masseteric muscle spasm as a normal response to suxamethonium. Br J Anaesth 1990; 64: 488-92
82. Lenzen C, Roewer N, Wappler F et al. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br J Anaesth 1993; 71: 242-6
83. Levitt RC, Nouri N, Jedlicka AE et al. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991; 11: 543-7
84. Levitt RC, Olckers A, Meyers S et al. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14: 562-6
85. Lister D, Hall GM, Lucke JN. Porcine malignant hyperthermia. III: Adrenergic blockade. Br J Anaesth 1976; 48: 831-8
86. Littleford JA, Patel LR, Bose D, Cameron CB, McKillop C. Masseter muscle spasm in children: implications of continuing the triggering anesthetic. Anesth Analg 1991; 72: 151-60
87. 2+] during a malignant hyperthermia episode in swine. Muscle Nerve 1988; 11: 82-8
88. Lucke JN, Denny H, Hall GM, Lovell R, Lister D. Porcine malignant hyperthermia. VI: The effects of bilateral adrenalectomy and pretreatment with bretylium on the halothane-induced response. Br J Anaesth 1978; 50: 241-6
89. MacKenzie AE, Korneluk RG, Zorzato F et al. The human ryanodine receptor gene: its mapping to 19q13.1, placement in a chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy. Am J Hum Genet 1990; 46: 1082-9
90. MacLennan DH, Duff C, Zorzato F et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-61
91. 2+ release channel. J Biol Chem 1987; 262: 6460-3
92. Manning BM, Quane KA, Lynch PJ et al. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Hum Mutat 1998; 11: 45-50
93. Manning BM, Quane KA, Ording H et al. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998; 62: 599-609
94. Marwaha J. Some mechanisms underlying actions of ketamine on electromechanical coupling in skeletal muscle. J Neurosci Res 1980; 5: 43-50
95. McCarthy TV, Healy JM, Heffron JJ et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-4
96. Michalek-Sauberer A, Fricker R, Gradwohl I, Gilly H. A case of suspected malignant hyperthermia during desflurane administration. Anesth Analg 1997; 85: 461-2
97. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263: 9310-5
98. Mitchell G, Heffron JJ. Procaine in porcine malignant hyperthermia. Br J Anaesth 1975; 47: 667-8
99. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-25
100. Moyes DG. Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 1973; 45: 1163-4
101. Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase catalyzed chain reaction. Methods Enzymol 1987; 155: 335-50
102. Ording H, Nielsen VG. Atracurium and its antagonism by neostigmine (plus glycopyrrolate) in patients susceptible to malignant hyperthermia. Br J Anaesth 1986; 58: 1001-4
103. Ording H, Brancadoro V, Cozzolino S et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-66
104. Ording H, Glahn K, Gardi T, Fagerlund T, Bendixen D, 4-Chloro-m-cresol test - a possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 1997; 41: 967-72
105. Otsuka H, Kemmotsu O. Malignant hyperthermia during sevoflurane anesthesia. Anesth Analg 1992; 75: 867
106. Phillips MS, Khanna VK, de Leon S, Frodis W, Britt BA, MacLennan DH. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Hum Mol Genet 1994; 3: 2181-6
107. Quane KA, Keating KE, Healy JM et al. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994; 23: 236-9
108. Quane KA, Ording H, Keating KE et al. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia. Br J Anaesth 1997; 79: 332-7
109. Ramirez JA, Cheetham ED, Laurence AS, Hopkins PM. Suxamethonium, masseter spasm and later malignant hyperthermia. Anaesthesia 1998; 53: 1111-6
110. Robinson RL, Monnier N, Wolz W et al. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6: 953-61
111. Robinson R, Curran JL, Hall WJ et al. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet 1998; 35: 196-201
112. Ruff RL. Calcium sensitivity of fast-and slow-twitch human muscle fibers. Muscle Nerve 1989; 12: 32-7
113. Ryan JF, Lopez JR, Sanchez VB, Sreter FA, Allen PD. Myoplasmic calcium changes precede metabolic and clinical signs of porcine malignant hyperthermia. Anesth Analg 1994; 79: 1007-11
114. Scholes NW, Jenden DJ, Creese R, Blumm JJ. The mechanism of action of ryanodine on skeletal muscle. J Pharmacol Exp Ther 1957; 121: 477-52
115. Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg 1993; 77: 297-304
116. Sudbrak R, Golla A, Hogan K et al. Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum Mol Genet 1993; 2: 857-62
117. Sudbrak R, Procaccio V, Klausnitzer M et al. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 1995; 56: 684-91
118. Sudo RT, Nelson TE. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle. J Pharmacol Exp Ther 1997; 282: 1331-6
119. 2+ channel. Anesthesiology 1996; 84: 1380-5
120. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272: 26332-9
121. 2+ release channels. J Biol Chem 1999; 274: 693-702
122. van der Spek AF. Triggering agents continued after masseter spasm: there is proof in this pudding. Anesth Analg 1991; 73: 364-5
123. van der Spek AF, Fang WB, Ashton-Miller JA, Stohler CS, Carlson DS, Schork MA. The effects of succinylcholine on mouth opening. Anesthesiology 1987; 67: 459-65
124. Wappler F, Roewer N, Lenzen C et al. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Br J Anaesth 1994; 72: 240-2
125. Wappler F, Roewer N, Kochling A, Scholz J, Steinfath M, Schulte am Esch J. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth Analg 1996; 82: 1230-6
126. Wappler F, Scholz J, von Richthofen V, Fiege M, Steinfath M, Schulte am Esch J. [4-Chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia]. [German]. Anasthesiol Intensivmed Notfallmed Schmerzther 1997; 32: 541-8
127. Wingard DW, Bobko S. Failure of lidocaine to trigger porcine malignant hyperthermia. Anesth Analg 1979; 58: 99-103
128. Xu L, Jones R, Meissner G. Effects of local anesthetics on single channel behavior of skeletal muscle calcium release channel. J Gen Physiol 1993; 101: 207-33
129. 2+ signal amplification in excitation-contraction coupling. EMBO J 1996; 15: 6172-7